Table 1.

Patient and exam features

Patient/exam featureEligible (N = 106)Final analysis set (N = 67)
Age at enrollment (years)
 Mean ± SD48.9 ± 12.048.9 ± 12.2
 Median (range)47.5 (24.0–75.0)49.0 (24.0–75.0)
Number of BI-RADS 3, 4, or 5 lesions, n (%)
 177 (72.6)57 (85.1)
 220 (18.9)6 (9.0)
 37 (6.6)4 (6.0)
 42 (1.9)0 (0.0)
Clinical indication for MRI, n (%)
 Evaluate extent of disease for known breast cancer47 (44.3)32 (47.8)
 Further evaluation of lesion detected on other imaging4 (3.8)2 (3.0)
 Short interval follow-up MRI6 (5.7)4 (6.0)
 Screening due to personal history of breast cancer6 (5.7)5 (7.5)
 Screening due to genetic risk or family history of breast cancer24 (22.6)12 (17.9)
 Other clinical indication9 (8.5)7 (10.4)
 Multiple clinical indications10 (9.4)5 (7.5)
MR (B0) field strength (tesla, T), n (%)
 1.5 T42 (39.6)27 (40.3)
 3.0 T64 (60.4)40 (59.7)
MR vendor platform, n (%)
 Philips 1.5 T26 (24.5)14 (20.9)
 Siemens 1.5 T4 (3.8)3 (4.5)
 GE 1.5 T12 (11.3)10 (14.9)
 Philips 3.0 T39 (36.8)26 (38.8)
 Siemens 3.0 T18 (17.0)10 (14.9)
 GE 3.0 T7 (6.6)4 (6.0)